Huminsulin Profil Iii Kwikpen (Insulin Human (Rdna))

Huminsulin Profil Iii Kwikpen is indicated for the treatment of diabetes mellitus where insulin therapy is required.

• Type 1 diabetes mellitus in adults and children.
• Type 2 diabetes mellitus when oral agents do not achieve glycemic targets.
• Adjunct to diet and exercise for basal insulin replacement.
• Use during pregnancy or lactation only when benefits outweigh risks (consult healthcare provider).
• May be employed in insulin pump therapy as a rapid‑acting component if compatible.

• Huminsulin Profil Iii Kwikpen delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the insulin receptor substrate, stimulating the phosphatidylinositol‑3‑kinase (PI3‑K) pathway and promoting translocation of GLUT‑4 transporters to the cell membrane, which increases glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose levels and improves metabolic control.

Adverse reactions reported with Huminsulin Profil Iii Kwikpen are generally related to its pharmacologic action and formulation.

Common

• Hypoglycemia (low blood glucose).
• Redness, swelling, or pain at the injection site.
• Lipodystrophy or local tissue changes.
• Mild weight gain.
• Transient rash or itching.

Serious

• Severe hypoglycemia requiring assistance.
• Anaphylactic or severe allergic reaction.
• Hypokalemia (low potassium levels).
• Significant edema or fluid retention.
• Insulin antibody syndrome causing unpredictable glucose control.

When prescribing or using Huminsulin Profil Iii Kwikpen, several safety considerations should be observed.

• Monitor blood glucose levels regularly to avoid hypo‑ or hyperglycemia.
• Adjust insulin dose in patients with renal or hepatic impairment.
• Use with caution in individuals with cardiovascular disease or heart failure.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients in the pen.
• Consider pregnancy and lactation only if the therapeutic benefit justifies potential risk.
• Store the pen according to manufacturer instructions, protecting it from extreme temperatures and direct sunlight.

Huminsulin Profil Iii Kwikpen may interact with other medications that affect glucose metabolism or insulin action.

Avoid

• Simultaneous administration of other insulin products without appropriate dose reduction.
• Co‑administration with insulin‑like growth factor‑1 (IGF‑1) therapy due to additive hypoglycemic effect.

Use with caution

• Concomitant sulfonylureas, meglitinides, or other glucose‑lowering agents that increase hypoglycemia risk.
• Beta‑blockers, which can mask symptoms of hypoglycemia.
• Corticosteroids, which may raise insulin requirements.
• Diuretics that alter potassium balance, potentially affecting insulin activity.